Pancreatic cancer (PC) remains a devastating disease with a five-year survival rate of <5%. The difficulty in making an early diagnosis and the frequent occurrence of metastasis are important reasons for this poor prognosis. In China, the incidence of PC has been increasing steadily. Therefore, the present study aimed to identify effective markers in the early and advanced stages of PC. The expression levels of complement C3, complement C4b1 and apolipoprotein E (ApoE) in the various stages of PC were assessed by immunohistochemistry, RT-PCR and western blotting. Additionally, the statistical significance of the results was analyzed. The expression levels of complement C3, complement C4b1 and apoE were higher in PC compared with normal pancreatic tissues. No correlations were observed between complement C3 and tumor TNM staging or lymph node metastasis. However, complement C4b1 and apoE were markedly correlated with tumor TNM staging and lymph node metastasis. Complement C3 may be used as a marker for the diagnosis of early-stage PC, while complement C4b1 and apoE are closely correlated with tumor development, reflecting the biological behavior of PC, and thus may be used as diagnostic markers of advanced PC.

Introduction

Pancreatic cancer (PC), which is highly malignant, is a relatively common malignancy. Early surgical resection is the only effective treatment. However, due to its deep location and lack of pronounced early symptoms and specific clinical manifestations, an early diagnosis is difficult to make. The rapid development, fast growth and frequent lymph node metastasis all contribute to the poor prognosis of PC. The majority of patients with PC are diagnosed when the disease has reached an advanced stage and only 1-3% of patients survive up to five years (1). Therefore, an early diagnosis and future clinical developmental research is important. Tumor markers are a considerable tool for early tumor detection and screening. Tumor markers help improve the diagnosis of early PC and promote the prognosis of PC. Carbohydrate antigen (CA) 19-9 is one of the most common clinically used tumor markers for PC; however, it lacks sufficient sensitivity and specificity in early diagnosis (2-4). Other tumor markers, including carcinoembryonic antigen (CEA) and CA125, are also being studied; however, not specifically for the early diagnosis of PC. Therefore, it is crucial to identify more sensitive and specific diagnostic tumor markers to screen high-risk patients and improve diagnosis (5,6).

Materials and methods

Ethical permission. The study protocol and consent forms conformed to the Declaration of Helsinki and were approved by the Ethics Review Board (ERB) Committee of the Affiliated Provincial Hospital of Anhui Medical University (Hefei, Anhui, China). Informed consent was obtained from all patients.

Patients and samples. Between May 2007 and May 2009, PC specimens from 38 cases that had complete medical records were collected from the Department of Pathology of the Affiliated Provincial Hospital of Anhui Medical University. These cases consisted of 18 males and 20 females, aged 16-81 years, with an average age of 60.5 years. The specimens were divided according to their histological grade. A total of 29 cases were highly-differentiated and nine cases were poorly-differentiated, while according to the International Union Against Cancer (UICC) staging of primary PC, there were seven stage I cases and 31 stage II-IV cases. There were 23 cases with lymph node metastasis and 15 without metastasis. These samples were used for the immunohistochemical analysis. Between May 2007 and May 2009, a further 20 fresh specimens of PC and 20 adjacent normal pancreatic tissues were collected, all of which were confirmed by their pathology. Among these 20 fresh specimens, there were eight males and 12 females, aged 16-76 years, with an average age of 60 years. These cases were also divided according to histological grade. There were 13 highly-differ-
entiated cases and seven poorly-differentiated cases, while the UICC staging of the original onset of PC showed four stage I cases and 16 stage II-IV cases. There were 13 cases with lymph node metastasis and seven cases without metastasis. These specimens were used for the RT-PCR analysis. None of the patients received pre-operative adjuvant treatment.

Immunohistochemistry. Immunohistochemical staining was performed on 4-μm sections of formalin-fixed paraffin-embedded samples using a standard avidin-biotin-peroxidase complex technique. Following deparaffinization with xylene and rehydration with serial gradient ethanol, the antigen was retrieved by heating the slides in 10 mM citrate buffer (pH 6.0) for 6 min in a microwave. The endogenous peroxidase was blocked with 0.3% hydrogen peroxide. The slides were subsequently incubated with a blocking protein (normal goat serum) for 10 min and primary antibody was added overnight at 4˚C followed by rinsing. Antibodies against C3, C4b1 and apolipoprotein E (ApoE; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) were used. The secondary biotinylated antibodies, PV6000 (C3), PV9003 (C4b1) and PV9003 (ApoE), were then applied for 30 min, followed by 30 min of incubation with streptavidin peroxidase (Dako LSAB + HRP kit; DAKO, Carpinteria, CA, USA). Subsequent to being rinsed, the slides were visualized with diaminobenzidine (DAB) chromogen solution (Dako) and counterstained with hematoxylin, followed by dehydration through graded ethanol and slide mounting. The control group was treated with phosphate-buffered saline (PBS) instead of the primary antibody. To ensure the specificity of the primary antibodies, consecutive tissue sections were incubated in the absence of the primary antibody. No immunostaining was observed in the normal human pancreas tissues (immunohistochemistry, magnification, x200; Figs. 1A, 2A, 3A). Weak positive C3 expression was observed in the normal human pancreas specimens (Fig. 1A), while positive C4b1 and ApoE expression occurred in the cytoplasm. The tissues were washed twice with cold PBS, then incubated in cold lysis buffer (1% Nonidet P40, 0.1% SDS, 150 mM Tris, 50 U/ml aprotinin and 1 mmol/l PMSF; pH 7.4) for 20 min at 4˚C. The cellular lysate was centrifuged for 2 min at 12,000 × g at 4˚C. The supernatants were collected as total cellular proteins. Quantitative analysis of the content was performed by the Lowry method and an equal amount of total protein from each sample was loaded onto SDS-PAGE gels. Following electrophoresis, the separated proteins were transferred to polyvinylidene fluoride membranes (Bio Trace PVDF; Pall Corporation, Port Washington, NY, USA) by electroblotting. Subsequently, the membrane was blocked with Tris-buffered saline (TBS) containing 5% skimmed milk for 1 h at room temperature, followed by incubation with primary antibodies against human C3, C4b1 and ApoE/TBS solution at 4˚C overnight. Subsequent to being washed, the membrane was incubated in HRP-linked secondary antibody/TBS solution for 1 h at room temperature. The western blotting reaction products with chemiluminescence reagents (SuperSignal-West Femto Trial kit; Pierce, Woburn, MA, USA) were visualized by radiography. Data analysis. All experiments were repeated at least three times and representative results are presented. Data are expressed as the mean ± standard deviation. P<0.05 was considered to indicate a statistically significant difference.

Results

Immunohistochemical analysis of C3, C4b1 and ApoE. The expression levels of C3, C4b1 and ApoE were significantly increased in the human PC samples (immunohistochemistry, magnification, x200; Figs. 1-3). Weak positive C3 expression was observed in the normal human pancreas specimens (Fig. 1A), while positive C3 expression was observed in the PC specimens (Fig. 1B). Weak positive C4b1 expression was observed in the normal human pancreas tissues (Fig. 2A), while positive C4b1 expression was observed in the PC specimens (Fig. 2B). Weak positive ApoE expression was observed in the normal human pancreas tissues (Fig. 3A), while positive ApoE expression was observed in the PC specimens (Fig. 3B).

The immunohistochemical staining showed that the expression of C3, C4b1 and ApoE occurred in the cytoplasm. The C3, C4b1 and ApoE expression levels in PC and normal human pancreatic tissues were compared and the staining results showed that the human PC tissue had higher C3, C4b1 and ApoE expression levels (Table II).

Table I. Primers of C3, C4, ApoE and β-actin.

| Gene    | Forward primer                                      | Reverse primer                                      |
|---------|-----------------------------------------------------|-----------------------------------------------------|
| C3      | 5'-TATCATCACCCCAACATCT-3'                           | 5'-CCCTCCACCTTTCTTCCGTA-3'                         |
| C4      | 5'-GGAAAGCAAGGAGGACTAT-3'                           | 5'-TTCAGCAGAACAAAGGTTG-3'                         |
| ApoE    | 5'-CTGCGTGTGCTGGTCA-3'                              | 5'-GCTCCTCGGTGCTCT-3'                              |
| β-actin | 5'-CAACTTCATCCACGTTCAACC-3'                         | 5'-GAAGAGCCAAGGACAGGTAC-3'                         |

ApoE, apolipoprotein E.
In the human PC specimens, an average of 73.68% (28/38), 76.32% (29/38) and 86.84% (33/38) expressed C3, C4b1 and ApoE, respectively, whereas only 42.11% (16/38), 26.32% (10/38) and 42.11% (16/38) of normal human pancreatic specimens expressed C3, C4b1 and ApoE, respectively ($\chi^2=7.77, 19.01$ and $16.6$, respectively; $P<0.01$).

Of the stage I PC specimens, 57.14% (4/7) expressed C3, while the rate of positive expression was 87.10% (27/31) in stage II-IV PC ($P=0.19$). In the PC specimens with lymphatic metastasis, 56.52% (13/23) expressed C3. The positive expression rate was 46.67% (7/15) in the PC tissues without lymphatic metastasis ($P=0.74$).

In the stage I PC specimens, 57.14% (4/7) expressed C3, while the rate of positive expression was 77.42% (24/31) in stage II-IV PC ($P=0.19$). In the PC specimens with lymphatic metastasis, 56.52% (13/23) expressed C3. The positive expression rate was 46.67% (7/15) in the PC tissues without lymphatic metastasis ($P=0.74$).

Figure 1. Immunohistochemical staining for C3. (A) Low C3 expression in normal pancreatic tissue. (B) High C3 expression in pancreatic cancer tissue (magnification, x200).

Figure 2. Immunohistochemical staining for C4b1. (A) Low C4b1 expression in normal pancreatic tissue. (B) High C4b1 expression in pancreatic cancer tissue (magnification, x200).

Figure 3. Immunohistochemical staining for ApoE. (A) Low ApoE expression in normal pancreatic tissue. (B) High ApoE expression in pancreatic cancer tissue (magnification, x200). ApoE, apolipoprotein E.

Figure 4. Expression of C3 (hc3), C4b1 (hc4) and ApoE mRNA. Lanes: (1) marker; (2) pancreatic cancer with lymph node metastasis; (3) stage I pancreatic cancer; (4) stage II-IV pancreatic cancer; (5) normal pancreatic tissue; and (6) pancreatic cancer without lymph node metastasis. ApoE, apolipoprotein E.
with lymphatic metastasis, 73.91 (17/23) and 78.26% (18/23) expressed C4b1 and ApoE, respectively, while the positive expression rates were 40.00 (6/15) and 33.33% (5/15) in the PC tissues without lymphatic metastasis (P<0.05).

**Table II. Correlations of the expression levels of C3, C4b1 and ApoE with pancreatic cancer and pathological factors.**

| Factor               | Category         | No. | C3               | C4b1             | ApoE              |
|----------------------|------------------|-----|------------------|------------------|------------------|
| Group                | Pancreatic cancer| 38  | 73.68% (28/38)   | 76.31% (29/38)   | 86.84% (33/38)   |
|                      | Normal pancreas  | 38  | 42.11% (16/38)   | 26.32% (10/38)   | 42.11% (16/38)   |
|                      | P-value          |     | <0.01            | <0.01            | <0.01            |
| UICC                 | Stage I          | 7   | 57.14% (4/7)     | 28.57% (2/7)     | 57.14% (4/7)     |
|                      | Stage II-IV      | 31  | 77.42% (24/31)   | 87.10% (27/31)   | 93.55% (29/31)   |
|                      | P-value          | >0.05| <0.05            | <0.05            | <0.05            |
| Lymph nodes metastasis| No              | 15  | 46.67% (7/15)    | 40.00% (6/15)    | 33.33% (5/15)    |
|                      | Yes              | 23  | 56.52% (13/23)   | 73.91% (17/23)   | 78.26% (18/23)   |
|                      | P-value          | >0.05| <0.05            | <0.05            | <0.05            |

ApoE, apolipoprotein E; UICC, International Union Against Cancer.

**Table III. Expression levels of C3, C4b1 and ApoE mRNA in pancreatic cancer.**

| Factor               | Category         | No. | C3 (±)           | C4b1 (±)            | ApoE (±)           |
|----------------------|------------------|-----|------------------|---------------------|-------------------|
| Group                | Pancreatic cancer| 20  | 5.93±0.82        | 7.94±0.95           | 4.83±0.65         |
|                      | Normal pancreas  | 20  | 4.05±1.12        | 1.22±0.57           | 1.78±0.74         |
|                      | P-value          |     | 6.03              | 27.21               | 13.77             |
|                      | t-value          |     | <0.01             | <0.01               | <0.01             |
| UICC                 | Stage I          | 4   | 6.51±0.28        | 7.21±0.12           | 4.28±0.12         |
|                      | Stage II-IV      | 16  | 5.78±0.85        | 9.14±1.02           | 5.28±0.81         |
|                      | P-value          |     | 1.66              | 7.33                | 4.74              |
|                      | t-value          |     | >0.05             | <0.01               | <0.01             |
| Lymph nodes metastasis| No              | 7   | 6.06±0.55        | 7.39±0.15           | 4.42±0.25         |
|                      | Yes              | 13  | 5.86±0.95        | 8.24±1.07           | 5.05±0.71         |
|                      | P-value          |     | 0.52              | 2.81                | 2.25              |
|                      | t-value          |     | >0.05             | <0.05               | <0.05             |

ApoE, apolipoprotein E; UICC, International Union Against Cancer.

**Western blotting of C3, C4b1 and ApoE protein expression.** Western blotting was performed to determine the relative C3, C4b1 and ApoE protein expression levels in five pancreatic group types (Fig. 5). As expected, C3, C4b1 and ApoE were each detected as single bands. β-actin was used as a control. The C3, C4b1 and ApoE protein expression levels were higher in the PC samples and lower in the normal pancreas samples. Furthermore, the expression levels of C3, C4b1 and ApoE were observed to be significantly different in the various phases of PC (Table IV).
Discussion

Complement is a sophisticated regulatory mechanism of the protein response system that is activated by antigen-antibody complexes or microorganisms and is involved in mediating inflammation, opsonophagocytosis, cell lysis, immune regulation and clearance of immune complexes. C3 is a mediatory inflammatory factor that, when activated, releases a variety of vasoactive substances (7,8), causing inflammation. In the present study, immunohistochemistry and western blotting demonstrated that the expression levels of C3 in the PC tissues were high, although the expression of C3 did not differ between the various stages of PC. The expression of C3 was not observed to be significantly different between the PC tissues with and without lymphatic metastasis. These findings indicated that C3 is involved in the early stages of PC, but not advanced PC. Therefore, C3 may be used as a serum biomarker in the early diagnosis of PC. The presence of C3, an important cytokine precursor involved in early PC, indicates that inflammation may be involved in the mechanism of PC. This is consistent with the study by Wang et al (9), which showed that the inflammatory regulator NF-κB was upregulated in PC tissues and cell lines. Certain studies have also reported that the expression of C3 is high in colon cancer serum (10), which may indicate that C3 is expressed specifically in the digestive tract.

C4b1 is not only closely associated with immune diseases, particularly systemic lupus erythematosus (SLE) (11), but it also has a crucial role in the induction of B cell self-tolerance (12). Theoretically, these are favorable factors for organisms fighting tumors, since antibodies bind to tumor antigens on tumor cells and are involved in directly killing them. Furthermore, immunoglobulin in B cell surfaces may combine with tumor antigens, inducing T cells to respond to tumors and creating antibodies, in collaboration with K cells, macrophages and complement, which are also able to kill the tumor cells [antibody-dependent cell-mediated cytotoxicity (ADCC)] and control tumor development and metastasis to a certain extent. Fujita et al analyzed the serum C4 levels of 43 cases of gastrectomy in gastric cancer patients (13). The results showed that higher levels of serum C4 were associated with higher recurrence rates. The present study also demonstrated that the expression of C4b1 in PC is high and markedly associated with the TNM stage of the tumor and with lymph node metastasis. The expression of C4b1 in the stage II-IV tumors and those with lymph node metastasis was significantly higher compared with the stage I tumors and those without lymph node metastasis, demonstrating that C4b1 is a marker of PC progression. We propose that the high expression levels of C4b1 in advanced PC may be the body’s protective immune response against the developmental process of PC. Therefore, this may generate new ideas for researching immune therapy for PC.

ApoE is a low-density lipoprotein (LDL) receptor ligand and its main biological function is the delivery of fat. ApoE is closely associated with lipoprotein metabolism, as well as the promotion of macrophage cholesterol overflow and the inhibition of platelet aggregation functions (14). The ApoE gene polymorphism produces the major human ApoE, generated in

Table IV. The GRAVY levels of C3, C4b1 and ApoE.

| Factor                    | Category          | No. | C3         | C4b1       | ApoE       |
|---------------------------|-------------------|-----|------------|------------|------------|
| Group                     | Pancreatic cancer | 20  | 1.63±0.28  | 1.25±0.18  | 2.57±0.22  |
|                           | Normal pancreas   | 20  | 0.88±0.19  | 0.65±0.13  | 1.28±0.24  |
| t-value                   |                   |     | 9.93       | 11.81      | 17.71      |
| P-value                   |                   |     | <0.01      | <0.01      | <0.01      |
| UIICC                     | Stage I           | 4   | 1.85±0.10  | 1.11±0.08  | 2.32±0.03  |
|                           | Stage II-IV       | 16  | 1.57±0.29  | 1.28±0.19  | 2.63±0.20  |
| t-value                   |                   |     | 1.85       | 2.87       | <0.05      |
| P-value                   |                   |     | >0.05      | <0.05      | 2.99       |
| Lymph nodes metastasis    | No                | 7   | 1.76±0.14  | 1.10±0.07  | 2.37±0.07  |
|                           | Yes               | 13  | 1.56±0.31  | 1.34±0.17  | 2.67±0.20  |
| t-value                   |                   |     | 2.05       | 4.26       | 3.70       |
| P-value                   |                   |     | >0.05      | <0.01      | <0.01      |

GRAVY, grand average of hydropathicity; ApoE, apolipoprotein E; UICC, International Union Against Cancer.
the liver and brain and other tissues, including mononuclear cells (such as macrophages). Between 60 and 80% of ApoE is synthesized in the liver. In addition, the human kidney, adrenal gland, bones and macrophages also synthesize ApoE. A previous study of ApoE was concerned with the association between ApoE and hyperlipidemia or related cardiovascular and cerebrovascular diseases (15), although in recent years, with more in-depth study, an increasing amount of research has been concerned with the role of ApoE in tumors. The expression of ApoE has been reported to be increased in a variety of tumors (16). Grant (17) reported that the upregulation of ApoE is a risk factor for prostate cancer. Andreotti et al (18) conducted a survey in Shanghai, China and showed that males with ApoE expression had an increased risk of suffering from bile duct cancer. The study by Moore et al (19) also revealed that ApoE and its gene variants increase the risk of renal cell cancer. Moreover, in the study of ApoE, the same close association was observed with gastrointestinal cancer (20). Mrkonjic et al (21) reported that diet (saturated fatty acid content) and ApoE isoforms synergistically increased the colorectal cancer risk. Gronborg et al (22) observed that the expression of ApoE in PC cells (Panc-1) was 20-fold higher compared with the normal control group. Yu et al (23) analyzed the expression of serum proteins in PC and normal controls by two-dimensional gel electrophoresis combined with a comparative analysis using tandem mass spectrometry and showed that the ApoE levels in the serum of patients with PC were significantly higher compared with the normal control group. Gillard et al (24) proposed that ApoE is distributed in the cells and is secreted by hepatic carcinoma cells. Huvila et al (25) demonstrated that ApoE has a positive correlation with endometrial adenocarcinoma and the degree of malignancy of the tumor. A higher expression of ApoE was associated with higher degrees of malignancy, indicating that ApoE reflects certain tumor biological characteristics. The present results showed that ApoE is highly expressed in PC. Furthermore, the ApoE levels were significantly higher in stage II-IV and lymph node metastatic PC tissues compared with stage I PC tissues and those without PC lymph node metastasis, thus showing that ApoE has an important role in the development of PC. This also indicates that ApoE reflects the biological characteristics of PC. The present results were consistent with those of Huvila et al (25). Martínez-Clemente et al (26) observed that ApoE was able to inhibit the expression of TNF-α, which is able to kill tumor cells. This also suggests that ApoE may be involved in tumor development. Additionally, the present results indicated that ApoE promotes the development of PC. Whether the mechanism is due to the inhibition of TNF-α remains to be clarified.

In conclusion, C3, C4b1 and ApoE are closely correlated with tumor development, reflecting the biological behavior of PC, and may be used as diagnostic markers of advanced PC.

References

1. Guo X and Cui Z: Current diagnosis and treatment of pancreatic cancer in China. Pancreas 31: 13-22, 2005.
2. Willett CG, Daly WJ and Warshaw AL: CA 19-9 is an index of response to neoadjuvant chemoradiation therapy in pancreatic cancer. Am J Surg 172: 350-352, 1996.
3. Goonetilleke KS and Siriwardena AK: Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 33: 266-270, 2007.
4. Marrelli D, Caruso S, Pedrazzani C, et al: CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Am J Surg 198: 333-339, 2009.
5. Gronborg M, Bunkenborg J, Kristiansen TZ, et al: Comprehensive proteomic analysis of human pancreatic juice. J Proteome Res 3: 1042-1055, 2004.
6. Cecconi D, Palmieri M and Donadelli M: Proteomics in pancreatic cancer research. Proteomics 11: 816-828, 2011.
7. Hugli TE: Structure and function of the anaphylatoxins. Springer Semin Immunopathol 7: 193-219, 1984.
8. Scholz W, McClurg MR, Cardenas GJ, et al: C5a-mediated release of interleukin 6 by human monocytes. Clin Immun Immunopathol 57: 297-307, 1990.
9. Wang W, Abbuzzesze JL, Evans DB, et al: The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 5: 119-127, 1999.
10. Habermann JK, Roblick UJ, Luke BT, et al: Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors. Gastroenterology 131: 1020-1029, 2006.
11. Pickering MC, Botto M, Taylor PR, et al: Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol 76: 227-324, 2000.
12. Einav S, Pozdnjakova OO, Ma M and Carroll MC: Complement C4 is protective for lupus disease independent of C3. J Immunol 168: 1015-1421, 2002.
13. Fujita T, Hara A and Yamazaki Y: The value of acute-phase protein measurements after curative gastric cancer surgery. Arch Surg 134: 73-75, 1999.
14. Greenow K, Pearce NJ and Ramji DP: The key role of apolipoprotein E in atherosclerosis. J Mol Med (Berl) 83: 329-342, 2005.
15. Trompet S, Jukema JW, Katan MB, et al: Apolipoprotein e genotype, plasma cholesterol, and cancer: a Mendelian randomization study. Am J Epidemiol 170: 1415-1421, 2009.
16. Tost Z, Marc J, Sok M and Cerne D: Increased apolipoprotein E gene expression and protein concentration in lung cancer tissue do not contribute to the clinical assessment of non-small cell lung cancer patients. Arch Med Res 39: 663-667, 2008.
17. Grant WB: A multicountry ecological study of risk-modifying factors for prostate cancer: apolipoprotein E epsilon4 as a risk factor and cereals as a risk reduction factor. Anticancer Res 30: 189-199, 2010.
18. Andreotti G, Chen J, Gao YT, et al: Polymorphisms of genes in the lipid metabolism pathway and risk of biliary tract cancers and stones: a population-based case-control study in Shanghai, China. Cancer Epidemiol Biomarkers Prev 17: 525-534, 2008.
19. Moore LE, Brennan P, Karami S, et al: Apolipoprotein E/C1 haplotypes modify renal cell carcinoma risk. Cancer Res 69: 8001-8008, 2009.
20. Beppu T, Gili-Bernabe P, Boveda-Ruiz D, et al: High incidence of tumors in diabetic thrombin activatable fibrinolysis inhibitor and apolipoprotein E double-deficient mice. J Tromb Haemost 8: 2514-2522, 2010.
21. Mrkonjic M, Chappell E, Pethe VV, et al: Association of apolipoprotein E polymorphisms and dietary factors in colorectal cancer. Br J Cancer 100: 1966-1974, 2009.
22. Gronborg M, Kristiansen TZ, Iwahori A, et al: Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Proteomics 5: 137-141, 2006.
23. Yu KH, Rustgi AK and Blair IA: Characterization of proteins in human pancreatic cancer serum using differential gel electrophoresis and tandem mass spectrometry. J Proteome Res 4: 1742-1751, 2005.
24. Gillard BK, Lin HY, Massey JB and Pownall HJ: Apolipoproteins A-I, A-II and E are independently distributed among intracellular and newly secreted HDL of human hepatoma cells. Biochim Biophys Acta 1791: 1125-1132, 2009.
25. Huvila J, Brandt A, Rojas CR, et al: Gene expression profiling of endometrial adenocarcinomas reveals increased apolipoprotein E expression in poorly differentiated tumors. Int J Gynecol Cancer 19: 1226-1231, 2009.
26. Martínez-Clemente M, Ferré N, González-Pérez A, et al: 5-lipoxygenase deficiency reduces hepatic inflammation and tumor necrosis factor alpha-induced hepatocyte damage in hyperlipidemia-prone ApoE-null mice. Hepatology 51: 817-827, 2010.